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Taking medication as agreed with a health care provider ‘i.e. adherence’, is a critically 
important health behaviour throughout life for both the prevention and treatment of illness 
and the maintenance of health (Osterberg & Blaschke, 2005).  From childhood use of 
antibiotics (Baguley, Lim, Bevan, Pallet, & Faust, 2012), to early adulthood use of oral 
contraceptives (Molloy, Graham, & McGuinness, 2012) to older adulthood use of 
cardiovascular risk reduction medications (O'Carroll, Chambers, Dennis, Sudlow, & 
Johnston, 2014), evidence based treatments such as these can have profound impact on health 
across the lifespan. Variability in the initiation, execution, and persistence of medication 
taking behaviour plays a significant role in explaining the difference between the trial based 
efficacy and ‘real-world’ effectiveness for many medications (Blaschke, Osterberg, Vrijens, 
& Urquhart, 2012). Medication adherence has therefore been the focus of systematic 
investigation for several decades by both behavioural and clinical scientists (DiMatteo, 
2004).   
Despite the long-standing and voluminous research describing the problem of non-
adherence, standardised, reliable and feasible evidence based solutions remain elusive and 
successes have been sporadic and isolated (Nieuwlaat et al., 2014). This shortcoming of 
behavioural science for medication taking behaviour is not completely at odds with other key 
health behaviours that require daily maintenance such as smoking cessation, physical activity 
and dietary behaviour, where similar challenges and modest successes have been encountered 
for those at high health risk (Bull, Dombrowski, McCleary, & Johnston, 2014). While many 
of the same key limitations identified in this literature pertain to medication adherence such 
as an absence of agreed theoretical and measurement approaches and limitations in study 
designs, medication taking has several fundamentally different behavioural characteristics.  
First, the behaviour can only usually be initiated following the granting of permission 
by a healthcare provider in the form of a prescription and some level of ongoing monitoring 
of the outcomes of this behaviour by the prescriber. Second, enactment of this behaviour is 
usually not a relatively prolonged social interaction where social influences of those also 
engaging in the behaviour can be important determinants, as is often the case for most of the 
other main behavioural contributors to health, e.g. physical activity, dietary behaviour, 
alcohol consumption, smoking and sexual behaviour (Mokdad, Marks, Stroup, & Gerberding, 
2004). Third, the efficacy of many medical treatments, particularly preventative chronic 
illness medication is not directly experienced following medication taking behaviour in the 
form of symptom relief or discernible improvements in vitality, therefore the usual conditions 
for causal learning are often absent, e.g. slow and small cause-effect relations, other 
behavioural or medical changes coinciding with the inhiation of a medication that may be 
interpreted as confounders (Rottman, Marcum, Thorpe, & Gellad, 2016). Indeed this role of 
unambiguous experiential feedback from medication actions is an increasingly acknowledged 
(McSharry, McGowan, Farmer, & French, 2016), but under-researched aspect of medication 
taking behaviour (Phillips, Cohen, Burns, Abrams, & Renninger, 2016). These unique 
characteristics contribute to the challenge of supporting the maintenance of this behaviour to 
improve health.  
In this special issue, we invited papers from colleagues that addressed key theoretical, 
methodological and intervention issues related to understanding and optimising medication 
adherence at various stages of the life course. The 7 papers published in this special issue 
address each of these 3 areas to varying degrees and provide a useful context to reflect on the 
science and practice of using psychological approaches to understand and improve 
medication adherence. While these set of empirical contributions to the literature identify a 
multitude of research and practice issues we would like to highlight what we see as the 6 
grand challenges for progressing science and practice in this area. 
Six grand challenges  
1. Measurement  
The papers led by Dima and colleagues (Dima et al., 2017) and Moran and colleagues 
(Moran et al., 2017)  are both concerned with the challenge of measuring inhaler adherence 
with the requisite feasibility, validity, reliability and sensitivity to allow progress in 
describing, predicting and intervening on this behaviour. The findings from Dima suggest 
that we can improve the way that we assess adherence in the context of asthma by refining 
how we use self-report methodology (Dima et al., 2017). Examining a specific medication 
taking behaviour, Moran and colleagues (Moran et al., 2017) intriguing findings show a 
striking lack of convergent validity between a new electronic method of continuously 
monitoring the frequency and quality of inhaler adherence and a range of established methods 
of assessing inhaler adherence. This suggests that commonly used measures may capture a 
broad range of phenomena that appear to be empirically unrelated but are conceptually 
connected as indices of inhaler adherence. These attempts to improve the measurement of 
adherence provide useful insights, but also cast doubt on the meaning of previous findings in 
the adherence literature where measurement heterogeneity is common (Nieuwlaat et al., 
2014). As in all areas of behavioural science, progress may continue to be slow across the 
adherence literature until measurement of these behaviours can be improved.  
2. Multi-morbidity and polypharmacy 
Many studies of adherence have focused on single conditions and single treatments, yet as the 
population ages many older patients have multiple conditions and are taking multiple 
treatments. Inauen and colleagues (Inauen et al., 2017) highlight that adherence may vary 
according to treatment type in those with multiple co-morbidities. Therefore, measures that 
attempt to capture general adherence may obscure both good and poor adherence for 
particular treatments. As multi-morbidity and polypharmacy (Barnett et al., 2012) is now the 
norm for many older adults with chronic disease, this presents a formidable challenge for 
measurement and intervention and indeed the generalisability of evidence based on single 
condition approaches. As alluded to earlier, multi-morbidity and polypharmacy also presents 
a challenge for patients to engage in the causal learning processes that may be necessary for 
successful initiation and maintenance of medication taking behaviour (Rottman et al., 2016).  
3. Feasible psychological targets for intervention 
A number of papers included in this issue drew on theoretical models or conceptual 
frameworks in an attempt to identify specific modifiable psychological targets for 
intervention. The papers led by Banas, Presseau and Cahir all attempt to identify key 
determinants of medication taking behaviour in the context of HIV (Banas, Lyimo, Hospers, 
van der Ven, & de Bruin, 2017), coronary heart disease (Presseau et al., 2016) and breast 
cancer treatment (Cahir, Dombrowski, Kennedy, Sharp, & Bennett, 2017), respectively. 
These findings vary in the extent to which they specify intervention targets that are malleable 
to intervention. While some identified potential targets for intervention can be linked to 
techniques that are known to be feasible for delivery in relatively low intensity interventions, 
e.g. perceived behavioural control (Banas et al., 2017) and strategies that reduce the cognitive 
load and effort required for medication taking behaviour (de Bruin et al., 2017), others refer 
to broader domains where the specificity and feasibility of related interventions is perhaps 
less clear, e.g. ‘Social Identity’ from the Theoretical Domains Framework (Presseau et al., 
2016). Ongoing work in the health behaviour change literature is currently attempting to link 
specific behaviour change techniques with specific constructs or mechanisms of action 
(Michie et al., 2016) and this may help identify feasible psychological targets for intervention 
to support medication taking behaviour in diverse conditions. 
4. A cumulative evidence base 
Building on the previously mentioned challenges relating to measurement and theory we are 
often faced with an adherence literature that is not cumulative (Nieuwlaat et al., 2014). 
Standardisation of measurement approaches such as those outlined by Cahir and colleagues 
(Cahir et al., 2017) can contribute to building a cumulative evidence base. It is frequently the 
case that quantitative synthesis of RCTs is not possible in the adherence literature despite 
adequate numbers of studies and relatively homogenous clinical samples (Molloy, O'Carroll, 
Witham, & McMurdo, 2012). While heterogeneity in measurement and theoretical 
approaches can contribute to this problem there are several other critical reasons that can 
prevent the emergence of a cumulative evidence base. As Morrissey and colleagues identify, 
reporting of methodology and results are often limited in ways that prevent replication and a 
clear synthesis of evidence (Morrissey et al., 2017). This includes poor reporting, coding and 
analysis of control or treatment as usual conditions (de Bruin et al., 2010; Oberje, Dima, 
Pijnappel, Prins, & de Bruin, 2015).  With the increasing mandatory use of reporting 
standards statements (Boutron et al., 2008; Hoffmann et al., 2014; Vandenbroucke et al., 
2014) it is likely that the quality of evidence reporting will improve. This will provide the 
opportunity for the necessary quantitative synthesis of evidence on medication adherence 
interventions and more reliable estimates of the potential effectiveness of medication 
adherence interventions on important health outcomes. 
5. Comparative effectiveness  
The argument for devoting valuable healthcare contact time for improving adherence to anti-
hypertensives, for example, is potentially weakened if we know that increasing physical 
activity might be modifiable, in a similar healthcare interaction, to a degree that would bring 
about a much greater benefit to blood pressure control and related health outcomes (Naci & 
Ioannidis, 2013). At present we know remarkably little about the comparative effectiveness 
of adherence interventions due to the absence of head-to-head trials comparing disparate 
medical or behavioural intervention strategies. Only if the health gain is substantially greater 
than alternative forms of healthcare intervention or indeed self-care e.g. physical activity and 
diet, can we justify devoting significant resources to improving medication adherence. 
Therefore, even if we had better measurement and cumulative evaluation of specific effective 
strategies to improve adherence, we will still need to identify the comparative effectiveness 
of adherence interventions to alternative uses of healthcare time and resources. The paper by 
Morrissey and colleagues (Morrissey et al., 2017) gives us an imprecise estimate of the 
effectiveness of behavioural intervention on a key health metric of adulthood, i.e. blood 
pressure control, that relates to many health conditions caused by cardiovascular disease. 
Future work should attempt to systematically assess how these behavioural interventions 
focusing on medication adherence compare with other potentially effective behavioural 
interventions using appropriate health economic analytic methods, e.g. increased physical 
activity to improve blood pressure control and subsequent health outcomes.  
6. Lifespan perspectives 
While a number of the health conditions that were the focus of study in the included papers in 
this special issue can be experienced throughout life, e.g. asthma (Dima et al., 2017) and HIV 
(Banas et al., 2017), the lifespan perspective does not feature strongly in this set of papers. 
This may not be surprising given that the samples were predominantly adult participants, 
however there is scope to incorporate more of the theory and evidence from developmental 
psychology into understanding adherence to treatment (Modi et al., 2012). In the case of 
asthma, for example, the psychological barriers and facilitators for inhaler adherence are 
likely to be very different if someone is seven, seventeen or seventy (Rhee, Belyea, 
Ciurzynski, & Brasch, 2009). While the paediatric and adult distinctions in supporting 
adherence are striking, the challenges in supporting self-management of health in adolescence 
and early adulthood are often not fully appreciated in healthcare (Campbell et al., 2016) or in 
adherence intervention development. This might reflect the strong emphasis on paediatric and 
adult medicine in many contexts and the relative neglect of the needs the those are in 
transition to adulthood (Arnett, 2000). Future work, particularly in relation to life-long 
conditions, should aim to incorporate our growing understanding of challenges of key life 
transitions. This will facilitate the design of developmentally appropriate medication 
adherence interventions.  
Conclusion 
While these challenges may pertain to the broader health behaviour change literature they 
have particular resonance for medication taking behaviour. The 7 papers in this special issue 
demonstrate that significant progress has been and is continuing to be made in improving our 
understanding of medication taking behaviour. However, the ultimate goal of developing a 
range of standardised, reliable and feasible evidence based solutions to poor adherence is 
likely to remain elusive for many health conditions if these challenges are not overcome.  
REFERENCES 
Arnett, J. J. (2000). Emerging adulthood. A theory of development from the late teens 
through the twenties. Am Psychol, 55(5), 469-480.  
Baguley, D., Lim, E., Bevan, A., Pallet, A., & Faust, S. N. (2012). Prescribing for children - 
taste and palatability affect adherence to antibiotics: a review. Arch Dis Child, 97(3), 
293-297. doi: 10.1136/archdischild-2011-300909 
Banas, K., Lyimo, R. A., Hospers, H. J., van der Ven, A., & de Bruin, M. (2017). Predicting 
adherence to combination antiretroviral therapy for HIV in Tanzania: A test of an 
extended theory of planned behaviour model. Psychol Health, 1-17. doi: 
10.1080/08870446.2017.1283037 
Barnett, K., Mercer, S. W., Norbury, M., Watt, G., Wyke, S., & Guthrie, B. (2012). 
Epidemiology of multimorbidity and implications for health care, research, and 
medical education: a cross-sectional study. Lancet, 380(9836), 37-43. doi: 
10.1016/S0140-6736(12)60240-2 
Blaschke, T. F., Osterberg, L., Vrijens, B., & Urquhart, J. (2012). Adherence to medications: 
insights arising from studies on the unreliable link between prescribed and actual drug 
dosing histories. Annu Rev Pharmacol Toxicol, 52, 275-301. doi: 10.1146/annurev-
pharmtox-011711-113247 
Boutron, I., Moher, D., Altman, D. G., Schulz, K. F., Ravaud, P., & Group, Consort. (2008). 
Extending the CONSORT statement to randomized trials of nonpharmacologic 
treatment: explanation and elaboration. Ann Intern Med, 148(4), 295-309.  
Bull, E. R., Dombrowski, S. U., McCleary, N., & Johnston, M. (2014). Are interventions for 
low-income groups effective in changing healthy eating, physical activity and 
smoking behaviours? A systematic review and meta-analysis. BMJ Open, 4(11), 
e006046. doi: 10.1136/bmjopen-2014-006046 
Cahir, C., Dombrowski, S. U., Kennedy, M. J., Sharp, L., & Bennett, K. (2017). Developing 
and validating a theoretical measure of modifiable influences on hormonal therapy 
medication taking behaviour in women with breast cancer. Psychol Health, 1-19. doi: 
10.1080/08870446.2017.1296151 
Campbell, F., Biggs, K., Aldiss, S. K., O'Neill, P. M., Clowes, M., McDonagh, J., . . . Gibson, 
F. (2016). Transition of care for adolescents from paediatric services to adult health 
services. Cochrane Database Syst Rev, 4, CD009794. doi: 
10.1002/14651858.CD009794.pub2 
de Bruin, M., Oberje, E. J., Viechtbauer, W., Nobel, H. E., Hiligsmann, M., van Nieuwkoop, 
C., . . . Prins, J. M. (2017). Effectiveness and cost-effectiveness of a nurse-delivered 
intervention to improve adherence to treatment for HIV: a pragmatic, multicentre, 
open-label, randomised clinical trial. Lancet Infect Dis. doi: 10.1016/S1473-
3099(16)30534-5 
de Bruin, M., Viechtbauer, W., Schaalma, H. P., Kok, G., Abraham, C., & Hospers, H. J. 
(2010). Standard care impact on effects of highly active antiretroviral therapy 
adherence interventions: A meta-analysis of randomized controlled trials. Arch Intern 
Med, 170(3), 240-250. doi: 10.1001/archinternmed.2009.536 
Dima, A. L., van Ganse, E., Laforest, L., Texier, N., de Bruin, M., & The Astro-Lab, Group. 
(2017). Measuring medication adherence in asthma: Development of a novel self-
report tool. Psychol Health, 1-20. doi: 10.1080/08870446.2017.1290248 
DiMatteo, M. R. (2004). Variations in patients' adherence to medical recommendations: a 
quantitative review of 50 years of research. Med Care, 42(3), 200-209.  
Hoffmann, T. C., Glasziou, P. P., Boutron, I., Milne, R., Perera, R., Moher, D., . . . Michie, S. 
(2014). Better reporting of interventions: template for intervention description and 
replication (TIDieR) checklist and guide. BMJ, 348, g1687. doi: 10.1136/bmj.g1687 
Inauen, J., Bierbauer, W., Luscher, J., Konig, C., Tobias, R., Ihle, A., . . . Scholz, U. (2017). 
Assessing adherence to multiple medications and in daily life among patients with 
multimorbidity. Psychol Health, 1-16. doi: 10.1080/08870446.2016.1275632 
McSharry, J., McGowan, L., Farmer, A. J., & French, D. P. (2016). Perceptions and 
experiences of taking oral medications for the treatment of Type 2 diabetes mellitus: a 
systematic review and meta-synthesis of qualitative studies. Diabet Med, 33(10), 
1330-1338. doi: 10.1111/dme.13152 
Michie, S., Carey, R. N., Johnston, M., Rothman, A. J., de Bruin, M., Kelly, M. P., & 
Connell, L. E. (2016). From Theory-Inspired to Theory-Based Interventions: A 
Protocol for Developing and Testing a Methodology for Linking Behaviour Change 
Techniques to Theoretical Mechanisms of Action. Ann Behav Med. doi: 
10.1007/s12160-016-9816-6 
Modi, A. C., Pai, A. L., Hommel, K. A., Hood, K. K., Cortina, S., Hilliard, M. E., . . . Drotar, 
D. (2012). Pediatric self-management: a framework for research, practice, and policy. 
Pediatrics, 129(2), e473-485. doi: 10.1542/peds.2011-1635 
Mokdad, A. H., Marks, J. S., Stroup, D. F., & Gerberding, J. L. (2004). Actual causes of 
death in the United States, 2000. JAMA, 291(10), 1238-1245. doi: 
10.1001/jama.291.10.1238 
Molloy, G. J., Graham, H., & McGuinness, H. (2012). Adherence to the oral contraceptive 
pill: a cross-sectional survey of modifiable behavioural determinants. BMC Public 
Health, 12, 838. doi: 10.1186/1471-2458-12-838 
Molloy, G. J., O'Carroll, R. E., Witham, M. D., & McMurdo, M. E. (2012). Interventions to 
enhance adherence to medications in patients with heart failure: a systematic review. 
Circ Heart Fail, 5(1), 126-133. doi: 10.1161/CIRCHEARTFAILURE.111.964569 
Moran, C., Doyle, F., Sulaiman, I., Bennett, K., Greene, G., Molloy, G, J. . . . Mellon, L. 
(2017). The INCA™ (Inhaler Compliance Assessment™) : A comparison with 
established measures of adherence. Psychol Health, 1-21. doi: 
10.1080/08870446.2017.1290243 
Morrissey, E. C., Durand, H., Nieuwlaat, R., Navarro, T., Haynes, R. B., Walsh, J. C., & 
Molloy, G. J. (2017). Effectiveness and content analysis of interventions to enhance 
medication adherence and blood pressure control in hypertension: A systematic 
review and meta-analysis. Psychol Health, 1-38. doi: 
10.1080/08870446.2016.1273356 
Naci, H., & Ioannidis, J. P. (2013). Comparative effectiveness of exercise and drug 
interventions on mortality outcomes: metaepidemiological study. BMJ, 347, f5577. 
doi: 10.1136/bmj.f5577 
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., . . . 
Haynes, R. B. (2014). Interventions for enhancing medication adherence. Cochrane 
Database Syst Rev(11), CD000011. doi: 10.1002/14651858.CD000011.pub4 
O'Carroll, R. E., Chambers, J. A., Dennis, M., Sudlow, C., & Johnston, M. (2014). Improving 
medication adherence in stroke survivors: mediators and moderators of treatment 
effects. Health Psychol, 33(10), 1241-1250. doi: 10.1037/hea0000082 
Oberje, E. J., Dima, A. L., Pijnappel, F. J., Prins, J. M., & de Bruin, M. (2015). Assessing 
treatment-as-usual provided to control groups in adherence trials: Exploring the use of 
an open-ended questionnaire for identifying behaviour change techniques. Psychol 
Health, 30(8), 897-910. doi: 10.1080/08870446.2014.1001392 
Osterberg, L., & Blaschke, T. (2005). Adherence to medication. N Engl J Med, 353(5), 487-
497. doi: 10.1056/NEJMra050100 
Phillips, L. A., Cohen, J., Burns, E., Abrams, J., & Renninger, S. (2016). Self-management of 
chronic illness: the role of 'habit' versus reflective factors in exercise and medication 
adherence. J Behav Med, 39(6), 1076-1091. doi: 10.1007/s10865-016-9732-z 
Presseau, J., Schwalm, J. D., Grimshaw, J. M., Witteman, H. O., Natarajan, M. K., Linklater, 
S., . . . Ivers, N. M. (2016). Identifying determinants of medication adherence 
following myocardial infarction using the Theoretical Domains Framework and the 
Health Action Process Approach. Psychol Health, 1-19. doi: 
10.1080/08870446.2016.1260724 
Rhee, H., Belyea, M. J., Ciurzynski, S., & Brasch, J. (2009). Barriers to asthma self-
management in adolescents: Relationships to psychosocial factors. Pediatr Pulmonol, 
44(2), 183-191. doi: 10.1002/ppul.20972 
Rottman, B. M., Marcum, Z. A., Thorpe, C. T., & Gellad, W. F.  (2016). Medication 
Adherence as a Learning Process: Insights from Cognitive Psychology. Health 
Psychol Rev, 1-37. doi: 10.1080/17437199.2016.1240624 
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gotzsche, P. C., Mulrow, C. D., Pocock, 
S. J., . . . Initiative, Strobe. (2014). Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg, 12(12), 
1500-1524. doi: 10.1016/j.ijsu.2014.07.014 
 
 
